联系我们

论文查询结果	返回搜索

论文编号：	15707
作者编号：	2320233807
上传时间：	2025/12/9 14:38:47
中文题目：	H医药公司的多元化发展战略研究
英文题目：	Research on the Diversification Strategy of H Pharmaceutical Company
指导老师：	田莉
中文关键字：	多元化战略；资源基础观；高端仿制药
英文关键字：	Diversification Strategy；Resource-Based View；High-end Generic Drugs
中文摘要：	在国家药品集中带量采购常态化推进与仿制药市场竞争加剧的背景下，H 医药公司因长期高度依赖降糖药单品（收入占比超 70%），面临营收波动加剧、利润空间压缩、抗风险能力薄弱等系统性经营风险，战略转型迫在眉睫。本文以 H 公司为研究对象，综合运用案例研究法、资源基础观（RBV）、价值链分析及专家访谈法，围绕 “如何有效实施多元化战略及所需关键资源能力” 的核心问题展开研究。 通过行业分析明确仿制药企业多元化的三大机遇：高端仿制药 / 复杂制剂凭借技术壁垒与高附加值形成差异化竞争；改良型新药（注册2 类）依托临床优势与政策支持实现利润突破；OTC、医疗器械及大健康领域与慢病业务关联性强，可通过资源复用降低跨界风险。其次，结合 H 公司现状评估发现，其具备生产平台、部分渠道及基础现金流等资源基础，但在高端研发、新市场开拓、跨业务管理等能力维度存在显著短板。 在此基础上，本文设计 H 公司 “1+N” 多元化战略框架：以降糖药为核心，培育心脑血管 / 神经精神药物、高端仿制药、OTC 产品、医疗器械及大健康服务等 N 个支柱业务。实施路径分三阶段推进：短期（1-3 年）聚焦高端仿制药（如盐酸普拉克索缓释片）与 OTC 渠道拓展，快速形成收入补充；中期布局医疗器械与大健康产品，构建多品类协同；长期（5 年以上）打造慢病健康管理生态，实现从 “药品销售” 向 “健康服务” 升级。同时，从组织架构（事业部制改革与 PMO 设立）、人才激励（多元化导向绩效体系）、资源整合（财务专项资金与技术平台建设）、风险管控（四维风险评估模型）四方面构建支撑体系，保障战略落地。 多元化是 H 公司破解单品依赖的必由之路，其中 “产品线深度多元化”（高端仿制 / 改良新药）为当前最优突破口，而组织变革、人才激励与资源聚焦是战略成功的三大核心支柱。本文研究可为同类仿制药企业应对集采压力、实现可持续发展提供实践参考。
英文摘要：	Against the backdrop of the normalized advancement of China's National Centralized Drug Procurement and the intensifying competition in the generic drug market, H Pharmaceutical Company faces systemic operational risks such as heightened revenue volatility, compressed profit margins, and weak risk resistance due to its long-term heavy reliance on a single anti-diabetic drug product , making strategic transformation imperative. This study takes H Company as the research object and comprehensively applies case study method, Resource-Based View (RBV), value chain analysis, and expert interviews to address the core issue of "how to effectively implement a diversification strategy and the key resources and capabilities required". Firstly, industry analysis identifies three major opportunities for generic drug enterprises to diversify: high-end generic drugs/complex formulations gain differentiated competitiveness through technological barriers and high added value ; improved new drugs achieve profit breakthroughs relying on clinical advantages and policy support ; the OTC, medical device, and big health sectors have strong relevance to chronic disease businesses, enabling reduced cross-border risks through resource reuse. Secondly, an assessment of H Company's current situation reveals that while it possesses basic resources such as production platforms, partial distribution channels, and fundamental cash flow, it has significant shortcomings in capabilities including high-end R&D, new market development , and cross-business management. Based on this, this paper designs a "1+N" diversification strategy framework for H Company: with anti-diabetic drugs as the core, and cultivating N pillar businesses including cardiovascular/neuropsychiatric drugs, high-end generic drugs, OTC products, medical devices, and big health services. The implementation path is advanced in three phases: in the short term, focus on high-end generic drugs and OTC channel expansion to quickly supplement revenue; in the medium term, deploy medical devices and big health products to build multi-category synergy; in the long term , create a chronic disease health management ecosystem to achieve an upgrade from "pharmaceutical sales" to "health services". Meanwhile, a support system is established from four aspects—organizational structure, talent incentives , resource integration, and risk management —to ensure the implementation of the strategy. The research conclusions indicate that diversification is the only way for H Company to break free from single-product dependence, among which "in-depth product line diversification" is the optimal breakthrough at present, and organizational reform, talent incentives, and resource concentration are the three core pillars for the success of the strategy. This study can provide practical references for similar generic drug enterprises to cope with the pressure of centralized procurement and achieve sustainable development.
查看全文：	预览  下载(下载需要进行登录)